A study of immunotherapy and targeted drugs for kidney cancer (sub study 03A)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
The main study (KEYMAKER-U03) is looking at combinations of immunotherapy and targeted drugs for a type of kidney cancer called renal cell cancer.
Sub study 03A is part of the main study. It is open to people with a type of kidney cancer called renal cell cancer that has:
- spread (
advanced cancer ) and - they haven’t had treatment for the cancer spread
More about this trial
Doctors can treat advanced renal cell cancer with the combination of pembrolizumab and lenvatinib.
Pembrolizumab is an immunotherapy. It works by helping the
Lenvatinib is a
- signals that tell the cancer cells to grow
- the cancer making new blood vessels which they need to grow
This stops the cancer cells from growing.
In this sub study the study team are looking at the following drugs:
- belzutifan (MK-6482)
- MK-4280A
- MK-1308A
- MK-7486A
Belzutifan is a drug doctors use to treat people with an
MK-4280A, MK-1308A and MK-7486A are combinations of pembrolizumab and another immunotherapy.
The main aims of the sub study are to find out:
- how safe these treatments are
- how well these treatments work
- what happens to these treatments in the body and how they affect the body
Who can enter
The following bullet points are a summary of the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this study if all of the following apply. You:
- have a type of kidney cancer called renal cell cancer that has spread into the surrounding tissue (locally advanced) or to another part of the body (metastatic). This is stage 4 renal cell cancer.
- have not had any
systemic treatment for your stage 4 renal cell cancer - have an area of cancer that the doctor can measure
- can take care of yourself but might not be able to do all your normal activities or do active work (Karnofsky performance score 70 to 100)
- are able to swallow tablets
- have a previous tissue sample (
biopsy ) the team can access. If this is not available you are willing to have a fresh biopsy taken. - have satisfactory blood test results
- are willing to use contraception during treatment and for a time after if there is any chance you or your partner could become pregnant
- are at least 18 years old
You can join the trial if you are having medication such as bisphosphonates for your bones. This is as long as you started it at least 2 weeks before going into one of the trial treatment groups (randomised).
Who can’t take part
Cancer related
You cannot join this study if any of these apply. You have:
- cancer spread to the brain or spinal cord. You might be able to join if you have had treatment for this spread. Your doctor will be able to tell you more about this.
- had a
scan that shows the cancer that is either very close to a major blood vessel or that the cancer has changed and looks like it is full of air or something similar. Your doctor will know if your scan shows this. - another cancer that has needed treatment or has got worse in the past 3 years. This is apart from
non melanoma skin cancer and anycarcinoma in situ (CIS) that has been successfully treated. - already had treatment or been put into a treatment group (
randomised ) for another sub study that is part of the main study. Your doctor will know if you have. - had an experimental drug or used a device as part of another clinical trial within 4 weeks of starting treatment
- had radiotherapy within 2 weeks of starting treatment. Or you are having corticosteroids due to side effects from radiotherapy.
Medical conditions
You cannot join this study if any of these apply. You:
- have
heart problems that could affect you taking part - have high blood pressure that isn’t well controlled
- have major surgery within 3 weeks of starting treatment
- have more than a certain amount of protein in your urine. Your doctor will do a urine test for this.
- have
lung problems such as inflammation or fluid on the lung that could affect you taking part. You might be able to take part if you had treatment for fluid on the lung. Your doctor will know if this is so. - are coughing up blood within the 3 weeks before starting treatment
- have an inflammatory bowel disease such as irritable bowel syndrome (IBS) or Crohn’s disease
- have an abnormal opening between 2 parts of the body or between the inside of the body and the outside of the body (a fistula). You might be able to join if it isn’t too bad. Ask your doctor they will know.
- have a problem with your
digestive system which affects how well your body absorbs medication taken by mouth - have an
immune system that isn’t working very well or you are taking medication that damps down the immune system within the 7 days of starting treatment. You can take steroids as long as it is a small dose. Your doctor will know what the dose is. - have an
autoimmune disease that has needed treatment in the past 2 years apart from certain ones. Your doctor will know which ones these are. - have HIV, hepatitis B or active hepatitis C. Or you have had any other infection that needs treatment.
- don’t have enough oxygen in your blood. Your doctor will test for this. Or you need to have oxygen to help you breathe.
- have had an
organ transplant . Or you have had a stem cell or bone marrow transplant from a donor (allogeneic transplant ). - have any other medical condition, mental health problem or social situation that could affect you taking part
Other
You cannot join this study if any of these apply. You:
- are allergic or sensitive to any of the treatments or any of their ingredients
- have a
live vaccine within the 30 days of starting treatment. You cannot have a live vaccine for 3 months after finishing treatment. The COVID-19 vaccines and some seasonal flu vaccines are not live vaccines. - are pregnant or breastfeeding
Trial design
This an international phase 1/2 study. The team need up to 390 people to take part with 27 people from the UK.
It is a randomised study. A computer puts you into treatment groups. Neither you nor your doctor chooses which group you are in. There are 5 treatment groups:
- pembrolizumab and lenvatinib
- MK-1308A and lenvatinib
- MK-4280A and lenvatinib
- pembrolizumab, lenvatinib and belzutifan
- MK-7684A and belzutifan
Pembrolizumab and lenvatinib is the
You have the following as a drip into a vein:
- pembrolizumab
- MK-1308A
- MK-4208A
- MK-7684A
You have pembrolizumab and MK-1308A once every 3 weeks or 6 weeks. You have them for up to 2 years.
You have MK-4208A and MK-7684A once every 3 weeks for up to 2 years.
Lenvatinib and belzutifan are tablets. You take the tablets once a day. Your doctor will tell how many to take and whether you take them on an empty stomach or with a meal.
You continue to have treatment as long as it is helping and the side effects aren’t too bad.
Samples for research
You give extra blood samples and tissue samples (
The team use these samples to:
- find out how the treatments affect the body and what happens to the treatments in the body
- look at the
genes in the cancer cells - look for substances (
biomarkers )
This can help researchers to find out:
- how well the treatments are working
- what affects how well the treatments work
- more about the treatments
They might also ask to store your samples for researchers to use in the future. Your samples will be anonymous.
Hospital visits
You see the doctor to have tests before taking part. These tests include:
- a
physical examination - blood tests
- CT scan or an MRI scan
- bone scan
- heart trace (ECG)
- heart scan (ECHO or
MUGA ) - urine test
You see the doctor regularly during treatment. This is:
- for blood tests and urine tests
- to see how you are
- to ask what daily activities you can do
- to ask about side effects
You have a scan at 3 months and then every 6 weeks while having treatment. If a scan shows your cancer is getting worse your doctor will talk to you about whether you should continue with the study treatment. They will also speak to you about what other treatments there might be if you do stop having the study treatment.
If you are having lenvatinib you will have regular heart traces and heart scans done. Your doctor will tell you how often you are to have them.
You see the doctor at the end of treatment and a month later. This is to see how you are and to ask about any side effects.
After treatment if your cancer has not got worse you see the doctor every 6 weeks or 12 weeks. You also have a scan.
If your cancer has got worse the doctor or nurse will contact you at least every 12 weeks to see how you are.
You might continue to see the doctor as part of study for up to 5 years.
Side effects
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Pembrolizumab, MK-1308A, MK-4280A and MK-7684A can affect the These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for. |
Researchers have looked at the combination of pembrolizumab and lenvatinib in other clinical trials. The side effects of these 2 drugs are the same whether you take them together or separately. The most common side effects from having pembrolizumab in combination with lenvatinib are:
- a low level of thyroid hormones causing tiredness, weight gain, feeling cold and constipation
- inflammation of the pancreas causing tummy pain, feeling or being sick
- inflammation of the adrenal glands causing tiredness, weight loss, weak muscles, feeling faint, diarrhoea and aching tummy, joints or muscles
- inflammation of the kidneys causing passing urine less often, cloudy urine, blood in the urine or lower back pain
MK-1308A is a new drug and there might be side effects we don’t know about yet. The most common side effects we do know of are:
- skin rash and or itchy skin
- inflammation of the lungs causing shortness of breath and or a cough
- too much thyroid hormone causing anxiety, feeling angry, trouble sleeping, weakness, trembling, sweating, tiredness and diarrhoea
- a low level of thyroid hormones causing tiredness, weight gain, feeling cold and constipation
MK-4280A is a new drug and there might be side effects we don’t know about yet. The most common side effects we do know about are:
- itchy skin and or rash
- tiredness (fatigue)
- diarrhoea
- a low level of thyroid hormones causing tiredness, weight gain, feeling cold and constipation
Doctors use belzutifan to treat renal cell cancer that has a link to Von Hippel-Lindau syndrome. But not for renal cell cancer by itself so there might be side effects we don’t know about yet when treating renal cell cancer only. The most common side effects of belzutifan we do know about are:
- a drop in the red blood cells
- tiredness (fatigue)
- shortness of breath
- feeling or being sick
- dizziness
- not enough oxygen in the body
- headache
- joint, muscle and or tummy pain
- swelling of the hands and legs
- constipation or diarrhoea
- an increase in a liver enzyme in the blood
- loss of appetite
- cough
- nose, throat and upper lung infection
- changes to how the kidneys work
- high blood pressure
- not enough water in the body (dehydration)
- weight gain
- trouble going to sleep or staying asleep (insomnia)
MK-7684A is a new drug and there might be side effects we don’t know about yet. The most common side effects we do know about are:
- tiredness (fatigue)
- skin rash and or itchy skin
- loss of appetite
- diarrhoea
- high temperature (fever)
- chills
- a low level of thyroid hormones causing tiredness, weight gain, feeling cold and constipation
- changes to how your pancreas and liver works
- a drop in red blood cells causing tiredness and shortness of breath
- joint pain
You might have reactions while you are having MK-7648A. These include:
- feeling dizzy or faint
- redness (flushing)
- rash
- high temperature
- feeling short of breath
- drop in blood pressure
- pain where MK-7648A is going into the vein
Tell your nurse if you have any of these when having MK-7648A.
We have more information about:
Your doctor will talk to you about the possible side effects and will answer any of your questions before you agree to take part.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Balaji Venugopal
Supported by
Merck, Sharp & Dohme
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040